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Primary pleural synovial sarcoma: 
a rare cause of hemorrhagic pleural effusion
Abstract
Primary pleural synovial sarcoma (PPSS) is a rare malignant pleural tumor comprising < 1% of all primary lung malignancies. 
Primary pleural mesothelioma (PPM) has many similar features that may cause a diagnostic dilemma due to overlapping clinical 
and histopathological features. We present the case of a young male with recurrent hemorrhagic pleural effusion without any 
obvious lung mass who was diagnosed with PPSS. This rare entity must be considered with a high index of suspicion while 
evaluating pleural tumors.
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Introduction
Synovial sarcomas (SS) are rare entities pre-
dominantly affecting the deep soft tissue of the 
upper and lower extremities, with the trunk and 
head-neck region being uncommon sites [1]. 
Primary synovial sarcomas of the pleura are rare 
malignant pleural tumors comprising < 1% of all 
primary lung malignancies [2]. It usually presents 
as a localized solid tumor and, less commonly, as 
diffuse pleural thickening. Common presenting 
features include chest pain, breathlessness, and 
hemothorax. There have been a few cases that 
have presented with pleural effusion. Differen-
tiating PPSS from primary pleural mesothelioma 
(PPM) can be a diagnostic challenge owing to 
PPM’s clinical and histological resemblance to 
PPSS. Immunohistochemistry (IHC) and molec-
ular genetics can help differentiate the two. We 
hereby report a case of Primary Pleural Synovial 
Sarcoma (PPSS) presenting with recurrent mas-
sive hemorrhagic pleural effusion in a young male.
Case report
A 26-year-old patient who was a non-smok-
ing laborer presented with chief complaints of 
breathlessness, cough, fever, and left-sided chest 
pain for one month. He was diagnosed by another 
clinic as having a tuberculous pleural effusion 
and was initiated on anti-tuberculous treatment 
with no relief. At presentation, he had marked 
respiratory distress but was hemodynamically 
stable. Chest radiograph from a posteroante-
rior view (Figure 1A) revealed a massive left 
pleural effusion which was drained to relieve 
the distress. Pleural fluid was hemorrhagic in 
appearance and a lymphocytic exudate. Con-
trast-enhanced computed tomogram (CECT) of 
the thorax showed a gross left pleural effusion 
with multiple pleural-based heterogeneously-en-
hancing irregular lesions, necrotic mediastinal 
lymphadenopathy, and contralateral metastatic 
canon-ball opacities (Figure 1B).
Transthoracic fine needle aspiration from 
the pleural-based mass lesion was suggestive of 
a poorly differentiated malignant tumor. Fiber-
optic bronchoscopy showed a narrowed lingular 
bronchus. Bronchoalveolar lavage and brush cy-
tology were negative for malignant cells, as were 
three pleural fluid samples. Multiple septations 
and grape-like nodules studding the parietal pleu-
ra (predominantly at the base) were visualized on 
thoracoscopy (Figure 1C). Thoracoscopic pleural 
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biopsy suggested a malignant small round cell 
tumor that was positive for TLE-1 (strong diffuse 
nuclear positive), CD-99 & Pan-CK (both strong 
diffuse membranous positive), and synaptophysin 
(mild diffuse membranous positive) on IHC, 
suggesting a final diagnosis of PPSS (Figure 2). 
A bone scan showed osteoblastic lesions sugges-
tive of skeletal metastasis in the lower one-third 
of the sacrum, left femur, and lateral condyle of 
left tibia. The patient was started on palliative 
doxorubicin and palliative radiotherapy.
Discussion
Synovial sarcomas are uncommon mesen-
chymal tumors that arise from primitive plu-
ripotent mesenchymal cells capable of synovial 
differentiation. Sarcomas involving the pleural 
cavity include chondrosarcoma, liposarcoma, 
osteosarcoma, malignant schwannoma, and sy-
novial sarcoma [3]. PPSS is a rare variety with 
only a few cases reported in literature. It usually 
occurs in the age group of 30–50 years [4] and 
has equal predilection for males and females [5]. 
PPSS most commonly presents with chest pain, 
shortness of breath, hemothorax, and pleural effu-
sion [2]. A case series of 19 PPSS cases indicated 
that the most common presentation was chest 
pain accompanied by breathlessness, while the 
least common presentation was pleural effusion 
[6]. Further, PPSSs are usually localised, solid 
pleural tumors but can, less commonly, present 
with diffuse pleural thickening [2]. Our patient 
presented with multiple pleural-based lesions 
with recurrent hemorrhagic pleural effusion.
Depending upon the type of cells, synovial 
sarcomas are classified histologically into mono-
phasic, biphasic, and poorly differentiated sub-
types. In the biphasic type, variable proportions 
of epithelial and spindle cell components are 
present. The monophasic type is predominantly 
composed of spindle cells. The poorly differen-
tiated types show small round tumor cells. Most 
PPSSs are monophasic [2].
IHC studies reveal that expression of TLE-1 is 
a sensitive and specific marker for synovial sarco-
ma [7]. This was seen in our case as well which, 
along with CD99 and Pan-CK positivity, led to 
a final diagnosis of PPSS. Genetic analysis may 
be helpful in diagnosis when IHC is inconclusive. 
t(X;18) (p11.2;q11.2) is the most common chro-
mosomal translocation found in more than 89% 
of synovial sarcomas regardless of its histological 
subtype. In our case, since IHC was confirmatory, 
genetic studies were not done.
The best treatment for synovial sarcoma is 
not yet clear. Though many treatment options are 
available, a multidisciplinary approach involving 
surgery, chemotherapy, and radiotherapy has been 
suggested. Radical resection is the first-line treat-
ment, and adjuvant radiotherapy is recommended 
for cases with incomplete resection. The efficacy 
of chemotherapy as first line treatment is unclear, 
however, improvement in overall survival has 
been described with the use of doxorubicin and 
ifosfamide. Neoadjuvant chemotherapy could be 
beneficial for reducing tumor volume and treating 
micrometastatic disease. Radiofrequency thermal 
ablation may be considered as an alternative 
treatment for inoperable patients [8].
Conclusion
PPSS is a rare disease. Its clinical and his-
tological resemblance to other primary pleural 
tumors, particularly mesothelioma, can pose a di-
agnostic challenge. The current case highlights 
the importance of maintaining a high clinical 
Figure 1. Chest X-ray (postero-anterior view) shows completely opaque left hemithorax with contralateral mediastinal shift (A). Contrast enhanced 
computed tomogram of thorax (B) shows gross left pleural effusion with multiple pleural-based irregular lesions (white arrows), necrotic mediastinal 
lymphadenopathy (black arrow) and contralateral metastatic canon-ball opacities (white arrowheads). Thoracoscopic image (C) showing multiple 
grape-like nodules studding parietal pleura
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Figure 2. Section from pleural biopsy (H&E 10×) shows small round malignant cells (A). Immunohistochemistry shows nuclear positivity for TLE-1 
and membranous positivity for pan-CK (B, D respectively). Tumor cells are negative for calretinin (C)
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suspicion of this diagnosis when evaluating 
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